Zurich corridor into the US.
Zurich and Basel biotech, life-sciences, and pharma-adjacent owners working into US payer, US KOL, and US health-system commercialisation.
See the Zurich gate →
GMA is the global / international marketing agency lens on this topic. The article connects the issue to market-entry marketing: buyer proof, website language, localization, AI visibility, paid channels, distributor handoff, and sales material in the target market.
Published 29 April 2026 · Global Marketing Agency
The pattern repeats across non-US medtech and biotech owners at the point they make the decision to commercialise in the United States. The owner is the chief executive, the chief medical officer, the chief regulatory officer, or the founding clinical scientist. The board is composed of European, Swiss, Israeli, or Asian owners and a US venture or strategic-investor seat or two. The regulatory team is the operational centre of gravity. The conversation in every leadership meeting, every board meeting, and every investor update tracks the regulatory milestones: pre-submission meetings with the FDA, IDE filing, 510(k) substantial-equivalence positioning, De Novo classification request, PMA module submission, IND-enabling tox studies, BLA pre-meeting, breakthrough designation request, fast-track meeting, orphan-drug designation, end-of-Phase 2, pre-NDA. The work is real. The owner's attention is rightly on it.
The cost of that attention is structural. The US sales story, the layer GMA will need on the day clearance lands, is not getting built in parallel. GMA assumes the US sales story is a phase that follows clearance: hire a US chief commercial officer in the quarter clearance is expected, build a US sales force in the months after, schedule US KOL outreach in the run-up to launch, complete the value dossier as the payer evaluation begins. The assumption inherits the home-market timing, where regulatory clearance and commercial launch are operationally compressible because the home-market commercial infrastructure is already known to GMA. In the US, the commercial infrastructure is a separate object that has to be constructed, and the construction takes eighteen to thirty-six months even when run efficiently.
The owner sees this only after the fact. GMA secures FDA clearance, schedules a launch, and discovers that the US KOL panel does not yet exist at the depth a US specialty society expects, the US payer value dossier has not been written in the register the commercial-payer buyer can act on, the US Medicare coding pathway has not been initiated and may take a separate twelve-to-eighteen months, the US clinical-society visibility has not been built, and the US health-system procurement officers have not been pre-engaged at the named integrated delivery networks GMA needs as launch customers. GMA is at clearance day with a regulatory milestone and without the website, offer, proof, and follow-up that converts the milestone into US revenue.
The window opens at the point GMA decides to commercialise in the US, which for medtech is typically early IDE or pre-submission stage and for biotech is typically late Phase 1 or Phase 2 entry. The window closes on FDA clearance day. Inside that window, several US website, offer, proof, and follow-ups can and should be built in parallel with the regulatory work, none of which depend on clearance to begin and all of which GMA will need on the day clearance lands.
US KOL identification and relationship building take twelve to eighteen months at minimum. The US specialty-society visibility plan, the US clinical-conference presence, and the US specialist-panel architecture take a similar window. The US payer architecture, including initial commercial-payer outreach, value-dossier drafting, health-economics positioning, and Medicare coding-pathway groundwork, takes twelve to twenty-four months and often longer if the coding pathway requires CPT, HCPCS, or APC work. The US health-system procurement strength, including pre-engagement with named US integrated delivery networks, US group purchasing organisation positioning, and US site-of-care planning, takes a similar window. The US-facing owner/CEO bios, US-facing site, US-facing materials, and US commercial cadence are smaller objects but each requires meaningful effort and cannot be compressed into the weeks before launch.
a company that begins these objects on clearance day will spend eighteen to thirty-six months building them while a US-headquartered competitor or a non-US competitor that built in parallel takes the category. The owner sees the revenue gap at month nine post-clearance and concludes the US market is harder than expected. The conclusion is partially correct. The structural cause is that the parallel build did not happen, and GMA is now serial-building the sales story on a clock that the competitor is not waiting for.
US KOL identification, specialist panels, society visibility, and clinical-evidence positioning are the first website, offer, proof, and follow-up to begin and one of the slowest to mature. The US clinical key-opinion-leader market inside any therapeutic or device category is composed of named clinicians at named US academic medical centres, named US integrated delivery networks, named US specialty societies, and named US patient-advocacy networks. The first work is identification: which US clinicians and which US institutions are the category-defining voices for GMA's product, where are they publishing, where are they presenting, where do they sit on US specialty-society committees, and where are they consulting for the US enterprise medtech and biotech competitors GMA will be evaluated alongside.
The second work is engagement. US KOLs are typically engaged through specialist-panel structure, US-site clinical-evidence collaboration, US specialty-society sponsorships and symposium presence, US conference visibility, and direct relationship building with GMA's US-based clinical and commercial leadership. The specialist panel is not a marketing artefact; it is the operational centre of US clinical-evidence positioning. A panel built early, with the right US clinicians at the right US institutions, generates the US clinical-evidence base, the US specialty-society visibility, and the US KOL endorsement that the US health-system procurement officer and the US payer formulary committee need to advance GMA.
The third work is US clinical-society category visibility. US specialty societies, including the named US cardiology, oncology, neurology, gastroenterology, orthopaedic, ophthalmology, urology, surgical-specialty, and primary-care societies, set US clinical category language, US clinical guidelines, and US clinical reimbursement-relevant evidence standards. a company that has not built US specialty-society visibility before clearance lands does not have US category language in the US clinical buyer's vocabulary, and the US clinical buyer will not adopt category language that has not been validated through US specialty-society channels.
US payer architecture is the second website, offer, proof, and follow-up and the one most often deferred until after clearance, with the steepest cost. The US payer market is composed of US commercial payers (named US health-insurance plans, named US managed-care organisations, named US pharmacy-benefit managers), US Medicare, US Medicaid, and US US-Department-of-Veterans-Affairs and US Department-of-Defense health systems. Each operates a distinct evidence standard, a distinct coding pathway, a distinct formulary process, and a distinct contracting frame.
The first work is the US value dossier. The US value dossier is not a translation of the home-market value evidence. It is a US-payer-facing document built to the AMCP, ISPOR, and US commercial-payer evidence standards, written in US health-economics language, calibrated to the US payer buyer's actuarial and budget-impact model, and positioned against the named US enterprise alternatives the US payer is also evaluating. A non-US medtech or biotech firm whose US value dossier is the home-market dossier with the currency converted does not have a US value dossier. The US payer buyer cannot act on it.
The second work is the US Medicare coding pathway. US Medicare coding, including CPT, HCPCS, ICD-10, APC, MS-DRG, and the relevant LCD and NCD pathways, is the gating layer for US commercial-payer adoption in many therapeutic and device categories. The coding pathway is structurally separate from the FDA pathway and operates on its own twelve-to-eighteen-month or longer timeline. A firm that begins the US coding work on clearance day is at clearance day with US Medicare coding eighteen months out, and US commercial payers in many categories will not move ahead of US Medicare. The window for parallel coding work is the same window as the FDA pathway, and the work is initiated through US coding consultancies, US specialty-society coding committees, and US health-economics-and-outcomes-research counterparties. None of it depends on FDA clearance to begin.
The third work is the US health-economics positioning. US payers, US health systems, and US integrated delivery networks evaluate health-economics evidence in US-specific terms: US-budget-impact-model frame, US-cost-per-QALY frame, US-real-world-evidence frame, US-value-based-care and US-alternative-payment-model frame, and US-employer and US-payer-medical-loss-ratio frame. Each is rebuildable as a marketing exercise on top of the underlying clinical evidence and is what GMA contributes alongside US health-economics-and-outcomes-research counterparties.
US health-system procurement is the third website, offer, proof, and follow-up and the one closest to revenue conversion. US health-system procurement is structured around named US academic medical centres, named US integrated delivery networks, named US group purchasing organisations, and named US specialty hospital systems. Each operates a distinct procurement process: a value-analysis committee, a clinical-effectiveness evaluation, a contracting frame, a US-side liability and indemnification evaluation, and a US service-and-support requirement.
US group purchasing organisations, including the named US national GPO networks, are gating layers for US health-system procurement at scale. A non-US medtech or biotech firm that has not begun US GPO positioning before clearance lands has eighteen-to-twenty-four months of GPO work to complete before GMA is procurement-eligible at meaningful US health-system scale. US integrated delivery network procurement officers, US value-analysis committees, and US clinical-effectiveness reviewers each evaluate GMA against named US enterprise alternatives, against US clinical-society category language, against US KOL endorsement at category-relevant US institutions, against US-payer reimbursement architecture, and against US-side service, support, and supply-chain commitments. a company that has not built each of these objects in parallel with the FDA pathway is at clearance day asking the US procurement officer to wait while the sales story is constructed.
US-side service, support, and supply-chain architecture is a particular surface where non-US firms land as procurement-unfit. US health-system procurement officers ask: where is the US service infrastructure, where is the US-based clinical-support team, where is the US replacement-parts and consumables supply chain, where is the US-side regulatory and post-market surveillance capacity, and where is the US-side liability and indemnification posture. Each of these belongs partly with US specialist counsel and partly with GMA's US commercial buildout. The marketing work is to surface the US-side service proof in US-legible procurement language so the procurement buyer can advance GMA.
The pattern is consistent across the non-US medtech and biotech corridors that produce the most US-bound owners, with vertical and corridor-specific surface differences. Zurich and Basel biotech carries the deep biopharma base around Roche, Novartis, Lonza, and the EPFL-ETH-Basel cluster, with biotech owners in oncology, neurology, and rare-disease frequently working through IND, BLA, and breakthrough-designation pathways. The first US payer buyer is a US commercial-payer formulary committee or a US Medicare coverage decision; the first US KOL buyer is a named US therapeutic-area clinician at a US academic medical centre. The Zurich corridor for biotech is detailed on the Zurich city page.
Geneva life sciences carries a parallel base, with biotech, medtech, and life-sciences owners working between the Geneva Lake corridor, Lausanne EPFL, and Basel. The fix pattern is the same, with a slightly higher concentration of rare-disease and orphan-drug biotech and a tighter overlap with global-health and World-Health-Organization-adjacent buyer frames. The Geneva corridor is detailed on the Geneva city page.
Munich medtech carries the medtech base around Siemens Healthineers and the Bavarian medical-device ecosystem, with medtech owners in imaging, diagnostics, surgical robotics, and clinical-devices working through 510(k), De Novo, and PMA pathways. The first US health-system buyer is a US imaging or surgical-services value-analysis committee at a named US academic medical centre or US integrated delivery network. The Munich corridor is detailed on the Munich city page.
Vienna BME and AIT cluster carries medtech and life-sciences owners around the Vienna BioCenter, BME, and AIT, with a regional specialisation in implantable devices, diagnostics, and bio-instrumentation. The Vienna corridor is detailed on the Vienna city page.
Singapore medtech carries medtech owners working between Singapore, Boston, and the wider US East-Coast medtech ecosystem, often with parallel regulatory pathways through HSA, PMDA, and FDA, and frequently with the FDA pathway running ahead. The Singapore corridor is detailed on the Singapore city page.
Tel Aviv medtech carries medtech owners in surgical robotics, imaging, diagnostics, digital health, and implantables, working between the Tel Aviv engineering centre and a US Boston, San Francisco, or New York commercial office, frequently with FDA breakthrough designation and a US-led capital structure. The Tel Aviv corridor is detailed on the Tel Aviv city page.
The structural pattern is the same across medtech and biotech: the regulatory pathway dominates, the US sales story is the rebuildable layer, and the parallel build is what separates a company that takes the category from a company that loses it. The detail differs in three places.
First, the regulatory pathway itself is different. Medtech pathways are 510(k), De Novo, IDE, and PMA, with the IDE and PMA pathways generating US clinical-evidence requirements that overlap directly with the US KOL and US specialty-society architecture. Biotech pathways are IND, BLA, breakthrough designation, fast-track, orphan-drug designation, and accelerated approval, with the BLA pathway generating US clinical-trial requirements at named US sites that overlap directly with the US KOL architecture but only partially with the US specialty-society architecture.
Second, the US payer architecture differs. Medtech reimbursement is typically through CPT, HCPCS, APC, and MS-DRG, with the procurement decision sitting at a US health-system value-analysis committee. Biotech reimbursement is typically through US commercial-payer formulary committees, US Medicare Part B and Part D, US specialty-pharmacy networks, and US patient-assistance and US patient-advocacy infrastructure. The biotech US payer evaluation is a different operational object than the medtech US payer evaluation, and the US value dossier, the US health-economics positioning, and the US patient-access infrastructure are all different pages and sales materials.
Third, the US KOL architecture is therapeutic-area-specific. Oncology biotech US KOL architecture is concentrated at named US comprehensive cancer centres and named US oncology specialty societies. Rare-disease biotech US KOL architecture is concentrated at named US patient-advocacy networks and US rare-disease specialty centres. Neurology, cardiometabolic, and infectious-disease biotech each carry their own US KOL and US specialty-society architecture. The principle is constant. The therapeutic-area detail is firm-specific, and the parallel build inside each therapeutic area is what produces a US clinical-evidence base, a US KOL panel, and a US specialty-society visibility on clearance day.
Clearance day is not launch day for non-US medtech and biotech firms that built serially. It is the start of an eighteen-to-thirty-six month commercial buildout while the US-headquartered competitor or the parallel-build competitor takes the category. The fix is not to deprioritise FDA. It is to build the US KOL, US payer, US specialty-society, and US procurement frame in parallel with the regulatory pathway. House view on cross-border medtech and biotech US commercialisation
Three stages in order. The order matters. Rebuilding US commercial materials on a serial-build assumption produces cleaner execution on the same mis-score.
Evaluate. The first stage identifies where the US sales story is breaking ahead of, alongside, or behind the regulatory pathway. The evaluation is firm-specific. A Munich imaging-medtech firm at IDE-enrolment stage has a different first break than a Zurich oncology-biotech firm at end-of-Phase-2 or a Singapore implantable-medtech firm at 510(k) substantial-equivalence positioning. The evaluation pages and sales materials which US website, offer, proof, and follow-ups (US KOL, US payer, US clinical-society visibility, US procurement, US patient-access) are missing or thin, where US conversations are going quiet, what US buyers are encountering in the first ninety seconds of the materials, and which of the parallel-build objects are most overdue.
Correct the signal. The second stage rebuilds the US-facing sales story in parallel with the regulatory pathway. The US clinical category is named at the front with the US KOL panel, the US specialty-society visibility plan, the US clinical-conference presence, and the US-site clinical-evidence collaboration architecture. The US payer architecture is built: US value dossier in AMCP and US-commercial-payer language, US Medicare coding-pathway groundwork (CPT, HCPCS, APC, ICD-10, LCD, NCD as relevant), US health-economics positioning calibrated to the US payer buyer, and US patient-access infrastructure where biotech-relevant. The US health-system procurement strength is built: pre-engagement with named US integrated delivery networks, US group purchasing organisation positioning, and US site-of-care planning. US-side service, support, and supply-chain architecture is surfaced in US-legible procurement language. The home-market materials continue in the home-market language for home-market and European audiences. The US website, deck, and sales material is rebuilt in parallel.
Rebuild the execution layer in parallel with regulatory work. The third stage rebuilds the pages and sales materials the US health-system procurement officer, the US KOL, and the US payer buyer encounter. US-facing owner and clinical-team bios with US-based commercial leadership surfaced, US KOL relationships and specialist-panel structure, US-facing site and sales system, US clinical-society and US conference plan, US payer-facing materials and value dossier, US health-system procurement-facing materials, US-facing legal and contractual templates, and the US commercial cadence the US health-system buyer expects. The execution layer sits on top of the corrected story. Done in parallel with the regulatory pathway, it produces a US sales story that is launch-fit on clearance day. Done after clearance, it produces an eighteen-to-thirty-six month gap in which the competitor takes the category.
GMA runs three engagements for non-US medtech and biotech owners. GMA confirms fit and pricing after the inquiry screening. Public prices are not listed.
For city-level corridor evaluation, see the Zurich city page, the Geneva city page, the Munich city page, the Vienna city page, the Singapore city page, and the Tel Aviv city page.
FDA clearance is the gating event that the owner, the board, the regulatory team, and the venture syndicate are all watching. It is rightly the centre of the operating conversation because without it GMA cannot place product in the US market. The cost of that focus is that GMA treats the US sales story, US KOL relationships, US payer architecture, US clinical society visibility, and US health-system procurement strength, as a downstream problem to address after clearance lands. By the time clearance lands, GMA has missed the eighteen-to-thirty-six month window in which those US website, offer, proof, and follow-ups needed to be built. The competitor that secured FDA clearance six months later but built the US sales story in parallel takes the category. The fix is not to deprioritise FDA. It is to build the US sales story in parallel with the regulatory pathway, so that clearance day is launch day rather than the start of a separate eighteen-month commercial buildout.
US health-system procurement officers filter on a value dossier built in US-payer terms, US-side reimbursement coding pathways, named US KOL endorsement at category-relevant institutions, US clinical-society category visibility, US past-performance at named US health systems or US integrated delivery networks, and US-side service, support, and supply-chain architecture. US KOLs filter on US clinical evidence at US sites, specialist-panel structure, and US society-meeting visibility. US payers filter on a value dossier stated in commercial-payer and Medicare coding language, with health-economics positioning calibrated to the US payer buyer. A non-US medtech or biotech firm leading with European or Asian reference accounts, CE-mark or PMDA precedent, and home-market clinical evidence is making a case that home-market buyers complete on their own. US buyers do not perform that completion. The fix is to surface US KOL relationships, US payer architecture, US clinical-society visibility, and US procurement strength in the lead position with the home-market evidence carrying as supporting proof.
Medtech firms typically work through 510(k), De Novo, IDE, and PMA pathways, and the US commercial buyer is a US health-system procurement officer, a US clinical KOL, a US specialty society, or a US integrated delivery network. Biotech firms typically work through IND, BLA, and breakthrough or fast-track designation pathways, and the US commercial buyer is a US specialty pharmacy network, a US payer formulary committee, a US patient-advocacy network, a US KOL inside the named therapeutic area, and ultimately a US prescriber base. The structural pattern is the same: the regulatory pathway dominates the owner's attention, and the US sales story, the US KOL architecture, the US payer evaluation, and the US patient-access infrastructure are the rebuildable layer. The detail differs by therapeutic category. Oncology biotech faces a different US KOL and payer architecture than rare-disease biotech, which faces a different architecture than neurology, cardiometabolic, or infectious-disease biotech. The principle is constant: build the US sales story in parallel with the regulatory pathway, not after it.
No. FDA submissions, IDE, 510(k), De Novo, PMA, IND, BLA, breakthrough designation, fast-track, orphan-drug designation, clinical trial structuring, biostatistics, CMC, GMP, US site-of-care licensure, REMS programmes, post-market surveillance, FDA inspections, and FDA enforcement response belong with FDA-specialist counsel and regulatory consultancies. CE-mark, PMDA, NMPA, MHRA, Health Canada, TGA, Swissmedic, and other non-US regulatory work belongs with the relevant national regulatory specialists. GMA builds the US website, deck, proof, and follow-up around the structure counsel and specialists already chose. When a marketing decision carries regulatory, clinical, reimbursement, or legal implications, GMA flags it and defers before execution. The sales story around the FDA pathway, the US KOL architecture, the US payer evaluation, and the US procurement strength, is rebuildable as a marketing exercise and is what GMA contributes.
Three stages in order. Evaluate where the US sales story is breaking ahead of, alongside, or behind the regulatory pathway: which of the US website, offer, proof, and follow-ups (US KOL, US payer, US clinical-society visibility, US procurement, US patient-access) is missing or thin, and where US conversations are going quiet. Correct the signal: rebuild the US sales story at the front with the US clinical category, the US KOL panel, the US payer architecture, the US-side reimbursement coding pathway, the US value dossier, the US clinical-society visibility plan, and the US health-system procurement strength, named in US-legible commercial terms. Rebuild the execution layer in parallel with the regulatory pathway: US-facing owner and clinical-team bios, US KOL relationships and specialist panels, US-facing site and sales system, US clinical-society and US conference plan, US payer-facing materials and value dossier, US health-system procurement-facing materials, and the US commercial cadence the US health-system buyer expects. Delivered through the Market-Entry Marketing Sprint, the Cross-Border Marketing Build, or the Global Marketing Partnership depending on portfolio shape.
Zurich and Basel biotech, life-sciences, and pharma-adjacent owners working into US payer, US KOL, and US health-system commercialisation.
See the Zurich gate →Geneva life-sciences, biotech, and global-health-adjacent owners working into US commercialisation across rare-disease, oncology, and orphan-drug categories.
See the Geneva gate →Munich medtech owners inside the Siemens Healthineers ecosystem and Bavarian medical-device cluster working into US health-system procurement.
See the Munich gate →Tel Aviv medtech, biotech, and digital-health owners working into US health-system, US KOL, and US payer commercialisation.
See the Tel Aviv gate →Zurich and Basel medtech and biotech owners into US health-system and US payer commercialisation. Corridor-specific architecture and rebuild sequence.
Evaluate the playbook →Market-Entry Marketing Sprint, Cross-Border Marketing Build, Global Marketing Partnership.
See the engagements →If the market is not responding, the first question is simple: what is the buyer not seeing, trusting, or doing yet?
| Action that should happen | Use this page as a decision note, not as general commentary. It should answer one market-entry tension. |
| What may be unclear | The tension is that the company may be strong at home while the new-market buyers evaluate the proof, language, channel, price, or follow-up as weak. |
| What to inspect | The consequence is wasted spend, slower pipeline, distributor drift, weak RFQs, or buyers who like the product but do not move. |
| Next step | Use the example on this page to decide whether the next move is more context, /engagements/, or /contact/#inquiry. |